Table 1.
Characteristics of patients treated with cabazitaxel
| N = 41 | |
|---|---|
| Age, y, median (range) | 71 (46‐85) |
| Age group, n (%) | |
| <75 y | 34 (82.9) |
| ≥75 y | 7 (17.1) |
| ECOG PS, n (%) | |
| 0 | 34 (82.9) |
| 1,2 | 7 (12.2) |
| PSA at baseline, ng/mL, median (range) | 136.5 (0.17‐11 660) |
| Sites involved, n (%) | |
| Bone | 40 (97.6) |
| Lymph nodes | 17 (38.6) |
| Prostate gland | 20 (48.8) |
| Lungs | 5 (12.2) |
| Liver | 4 (9.8) |
| Prior surgery, n (%) | 10 (22.7) |
| Prior radiotherapy, n (%) | 19 (43.2) |
| Prior 2nd AR targeting lines, n (%) | |
| ENZA | 25 (60.9) |
| ABI | 19 (46.3) |
| The number of treatment prior to cabazitaxel, n (%) | |
| 1 | 3 (7.3) |
| 2 | 8 (19.5) |
| 3 | 16 (39.0) |
| 4 or more | 14 (34.1) |
| Total prior docetaxel cycle, median (range) | 8 (3‐43) |
ABI, abiraterone acetate; AR, androgen receptor; ENZA, enzalutamide; PS, performance status; PSA, prostate‐specific antigen.